These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Nabhan C; Gajria D; Krett NL; Gandhi V; Ghias K; Rosen ST Mol Cancer Ther; 2002 Nov; 1(13):1221-7. PubMed ID: 12479703 [TBL] [Abstract][Full Text] [Related]
27. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine. Oo ZY; Proctor M; Stevenson AJ; Nazareth D; Fernando M; Daignault SM; Lanagan C; Walpole S; Bonazzi V; Škalamera D; Snell C; Haass NK; Larsen JE; Gabrielli B Mol Oncol; 2019 Jul; 13(7):1503-1518. PubMed ID: 31044505 [TBL] [Abstract][Full Text] [Related]
28. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Liu XJ; Nowak B; Wang YQ; Plunkett W Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266 [TBL] [Abstract][Full Text] [Related]
29. Increased cytotoxicity of 2',2'-difluoro-2'-deoxycytidine in human leukemic cell-lines after a preincubation with cyclopentenyl cytosine. Verschuur AC; Van Gennip AH; Leen R; Van Kuilenburg AB Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1517-21. PubMed ID: 15571289 [TBL] [Abstract][Full Text] [Related]
30. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer. Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490 [TBL] [Abstract][Full Text] [Related]
31. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine. Muggia F; Diaz I; Peters GJ Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148 [TBL] [Abstract][Full Text] [Related]
32. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509 [TBL] [Abstract][Full Text] [Related]
33. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Santini V; Bernabei A; Gozzini A; Scappini B; Zoccolante A; D'Ippolito G; Figuccia M; Ferrini PR Haematologica; 1997; 82(1):11-5. PubMed ID: 9172997 [TBL] [Abstract][Full Text] [Related]
34. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929 [TBL] [Abstract][Full Text] [Related]
35. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. Smid K; Van Moorsel CJ; Noordhuis P; Voorn DA; Peters GJ Int J Oncol; 2001 Jul; 19(1):157-62. PubMed ID: 11408937 [TBL] [Abstract][Full Text] [Related]
36. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine. Ostruszka LJ; Shewach DS Cancer Res; 2000 Nov; 60(21):6080-8. PubMed ID: 11085531 [TBL] [Abstract][Full Text] [Related]
38. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Bernhaus A; Ozsvar-Kozma M; Saiko P; Jaschke M; Lackner A; Grusch M; Horvath Z; Madlener S; Krupitza G; Handler N; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T Invest New Drugs; 2009 Oct; 27(5):393-401. PubMed ID: 18841326 [TBL] [Abstract][Full Text] [Related]
39. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Azuma A; Huang P; Matsuda A; Plunkett W Mol Pharmacol; 2001 Apr; 59(4):725-31. PubMed ID: 11259616 [TBL] [Abstract][Full Text] [Related]
40. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Zhou B; Su L; Hu S; Hu W; Yip ML; Wu J; Gaur S; Smith DL; Yuan YC; Synold TW; Horne D; Yen Y Cancer Res; 2013 Nov; 73(21):6484-93. PubMed ID: 24072748 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]